Stock Research for INSY

INSY

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

INSY Stock Chart & Research Data

The INSY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the INSY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


INSY Due diligence Resources & Stock Charts

The INSY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View INSY Detailed Price Forecast - CNN Money CNN View INSY Detailed Summary - Google Finance
Yahoo View INSY Detailed Summary - Yahoo! Finance Zacks View INSY Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View INSY Trends & Analysis - Trade-Ideas Barrons View INSY Major Holders - Barrons
NASDAQ View INSY Call Transcripts - NASDAQ Seeking View INSY Breaking News & Analysis - Seeking Alpha
Spotlight View INSY Annual Report - CompanySpotlight.com OTC Report View INSY OTC Short Report - OTCShortReport.com
TradeKing View INSY Fundamentals - TradeKing Charts View INSY SEC Filings - Bar Chart
WSJ View Historical Prices for INSY - The WSJ Morningstar View Performance/Total Return for INSY - Morningstar
MarketWatch View the Analyst Estimates for INSY - MarketWatch CNBC View the Earnings History for INSY - CNBC
StockMarketWatch View the INSY Earnings - StockMarketWatch MacroAxis View INSY Buy or Sell Recommendations - MacroAxis
Bullish View the INSY Bullish Patterns - American Bulls Short Pains View INSY Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View INSY Stock Mentions - StockTwits PennyStocks View INSY Stock Mentions - PennyStockTweets
Twitter View INSY Stock Mentions - Twitter Invest Hub View INSY Investment Forum News - Investor Hub
Yahoo View INSY Stock Mentions - Yahoo! Message Board Seeking Alpha View INSY Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for INSY - SECform4.com Insider Cow View Insider Transactions for INSY - Insider Cow
CNBC View INSY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for INSY - OTC Markets
Yahoo View Insider Transactions for INSY - Yahoo! Finance NASDAQ View Institutional Holdings for INSY - NASDAQ


Stock Charts

FinViz View INSY Stock Insight & Charts - FinViz.com StockCharts View INSY Investment Charts - StockCharts.com
BarChart View INSY Stock Overview & Charts - BarChart Trading View View INSY User Generated Charts - Trading View




Latest Financial News for INSY


Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use
Posted on Thursday May 23, 2019

Cannabis company Canopy Growth (NYSE:CGC) may have just secured its highest-profile celebrity endorsement yet. Perhaps only topped by the well-publicized relationship between Oprah Winfrey and Weight Watchers (NASDAQ:WW), lifestyle icon Martha Stewart just revealed she invested in an undisclosed stake in Canopy Growth stock because cannabis and cannabinol products are an "alternative to opioids."Source: Shutterstock She's probably not wrong. Insys Therapeutics (NASDAQ:INSY) and Cara Therapeutics (NASDAQ:CARA) are just a couple of several pharmaceutical companies developing ways to use the unique properties of the plant to make effective but not addictive pain-killers.Still, some industry experts are skeptical, and even if the CBD is the basis for an alternative to opioids the world hopes it will be, Canopy Growth role in that sliver of the cannabis movement is modest, at best. Its rise to prominence has been almost entirely driven by recreational use.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTake a closer look at the company though, and you'll find a handful of the (too many) different entities Canopy Growth owns are actually taking aim at the opioid epidemic. * 7 Safe Stocks to Buy for Anxious Investors Pain Relief and Canopy Growth StockThe 77-year Stewart is as in-touch with societal trends as any millennial is, recently explaining of her investment in Canopy Growth stock to Create & Cultivate's founder Jaclyn Johnson, "Well, it's the modern thing, and it's an alternative to opioids of course."It is indeed the modern thing to do. More than 60% of Americans now favor legalizing marijuana, and cannabis has promise as a strong pain reliever.The former model and TV show host went on to undermine her case, however, adding, "I have a lot of animals, and I would love to be able to relieve stress or arthritis or other kinds of problems that my horses, my dogs, my cats experience. We're working on that first, and we're working on additions to human food stuffs, and also on cosmetics."To-date, recreational marijuana has been the crux of the story surrounding Canopy Growth. Of its fiscal Q3 sales of 10,102 kilograms, up 334% year-over-year, the vast majority of it was for recreational usage.The company isn't ignoring its potential role as a supplier of cannabis for true medicinal purposes though. Pharma and Canopy Growth StockAs of the latest look, Canopy owns eight diverse brands, including the relatively new Spectrum Therapeutics, which serves as "the company's healthcare professional and patient-facing identity in medical markets in Canada and around the world." While new, the division has still been undersold.Spectrum Therapeutics is a three-branch unit. Canadian consumers are likely most familiar with Spectrum Cannabis, which supplies medical cannabis using a clever-though-not-complicated color-coding system.It's the other two divisions of Spectrum, however, that quietly look and feel more like pharma companies than a means of simply scoring a high.Canopy Health Innovations, for instance, has secured 38 provisional patents in the United States with more on the way. Overseas, it's involved in eleven different drug-development trials.Cannabinoid Compound Company, also referred to as C3, is Europe's largest cannabinoid-based pharmaceuticals company. Granted, that doesn't necessarily mean a whole lot just yet. The company's dronabinol, however, can be "prescribed by doctors in Germany for any type of chronic pain, and for any condition in palliative care."It's a credible start towards becoming the opioid alternative Martha Stewart believes is possible.Adding to that credibility is the fact that the NFL is exploring the use of cannabis as a means of treating players' pains. That follows a partnership forged between the NHL Alumni Association and Canopy Growth earlier this year, to explore cannabinoids as a means of treating post-concussion neurological diseases… an area the NFL should be exploring as well. Looking Ahead for Canopy Growth StockDon't misread the message. An investment in Canopy Growth stock is an investment in many things, but an investment in opioid alternatives is the least of them. And, it could take years for the prescription-based use of cannabis to catch up with Canopy's recreational business. If that's the impact Stewart is betting on, it could be a long and rocky wait.It's still on the radar though. And, with the opioid market expected to be worth roughly $35 billion by 2025, it's a prospect that would certainly make for a solid second-act from the company. Or, maybe a third act, if the United States legalizes marijuana at the federal level. While certainly game-changing, recreational usage can't drive double-digit and triple-digit growth forever.Besides, the bigger the recreational market gets, the more competitive it becomes, and we've already seen the prices of marijuana fall as it becomes increasingly commoditized.Prescription-based products, preferably co-developed with a major partner, could prove to be a key means for Canopy Growth to differentiate itself and establish a longer-lasting, better-defended growth engine. You've just heard very little about the potential opportunity because it's such a long-term one.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Safe Stocks to Buy for Anxious Investors * 4 Tech Stocks Looking Vulnerable * Should You Buy, Sell, Or Hold These 7 Hot IPO Stocks? Compare Brokers The post Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use appeared first on InvestorPlace.


You Can Get Buy Signals From Short Selling
Posted on Wednesday May 22, 2019

You may be surprised to hear this, but a large amount of short interest in a stock could actually be a buy signal.What is short selling a stock? It's selling a stock that you don't own with the intention of buying it back at a lower price in the future, usually using options. And short interest is the number of shares that are sold short that haven't been bought back yet. It is usually expressed as a ratio of shares that are short to the total number of outstanding shares.The short interest can also be expressed as "Days to Cover." This is the number of short shares divided by the average daily trading volume. In other words, it is the number of days that it would take for all the short shares to be bought back.InvestorPlace - Stock Market News, Stock Advice & Trading TipsI should note, this number should be considered understated, because it assumes purchasing 100% of the volume. This would be impossible in normal markets. It would be more realistic to assume that short sellers could only buy about 10%-15% of the average daily volume with adversely affecting the price. * 7 Safe Stocks to Buy for Anxious Investors You should pay attention to this because really high short-interest could be a bullish signal. This is because these shares need to be bought back. These short-sellers will all eventually become buyers! Trupanion (TRUP)Trupanion (NASDAQ:TRUP) provides medical insurance for cats and dogs. It has a subscription business and also offers insurance to companies that can provide it as a benefit to their employees.There are about 11.2 million shares currently short. This is 38% of the outstanding float. The average daily volume recently is about 145,000. That means the days to cover would be about 77. And remember, that assumes buying 100% of the volume.It would be more realistic to assume that one could only trade about 10% of the volume without adversely affecting the price. That means it could take years for the shorts to cover all of their positions!Wall Street seems to disagree with the shorts. Six firms follow it and the all have buy ratings on it. The average price target is $40. Accelerate Diagnostics (AXDX)Accelerate Diagnostics (NASDAQ:AXDX) engages in developing and selling instruments that are used to fight infectious pathogens.There are 14.1 million shares currently short in this company. That is 52% of the float. That means that there are guaranteed buyers for about half of the company's stock! Assuming that they buy 10% of the average daily volume, it would take about two years to cover it. * 7 Stocks to Buy for Over 20% Upside Potential All four of the analysts who cover this have a buy rating on it according to Yahoo Finance. OptiNose (OPTN)OptiNose (NASDAQ:OPTN) develops and sells products that are for the treatment of ear, nose, throat and allergy illnesses.The short-interest is 7.9 million, or about 49% of the float. Over the past year, the price of the stock has fallen from $30 to current levels around $9.Wall Street doesn't feel as bad about this company's prospects as the short sellers do. It likes this stock. All four analysts that follow it have it rated as a buy and the average target price is $25. That is about three times higher then where it is currently trading. Energy Recovery (ERII)Energy Recovery (NASDAQ:ERII) develops and sells products that are for industrial fluid flow application. Their customers include oil and gas companies.5.5 million shares are currently short. That is about 14% of the float. It isn't as much as the other companies, but it is still pretty high. It only trades about 112,000 on a typical day, so that would give a days to cover number of about 50. Using our estimate of being able to only acquire about 10%-15% of the volume that trades with adversely affecting the price, it would take over a year to cover. * 7 High-Yield REITs to Buy (Even When the Market Tanks) There are six buys on this company. The average target price is about $16, which is about 60% above current prices. Seres Therapeutics (MCRB)Seres Therapeutics (NASDAQ:MCRB) creates medicines "using live bacteria to treat diseases that result from functional deficiencies in the microbiome."The share price fell dramatically over the past month. The current short interest is 5.3 million of the float. That is about 25%. With an average daily volume of about 111,000, the days to cover is 48.This company is followed by nine Wall Street firms. Seven have it rated as a buy and the other two have it as a hold. The average target price is $11 and it is currently trading below $5. Theravance Biopharma (TBPH)Theravance Biopharma (NASDAQ:TBPH) is a biopharmaceutical company. It focuses and the research, development and commercialization of small molecule medicines.The short-interest ratio here is "only" 15%, or 6.3 million shares. The stock only trades about 154,000 shares on a typical day, so that is 41 days to cover.Remember, it is safe to assume that they can buy about 10% of the volume without adversely affecting the price. * 6 Chinese Stocks That Could Pop On a Trade Deal Seven firms follow this company. Four of them have it rated a buy and three have it as a sell. The average target price is just over $38 per share.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Safe Stocks to Buy for Anxious Investors * 4 Tech Stocks Looking Vulnerable * Should You Buy, Sell, Or Hold These 7 Hot IPO Stocks? Compare Brokers The post You Can Get Buy Signals From Short Selling appeared first on InvestorPlace.


The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Posted on Saturday May 18, 2019

Biotech stocks came under pressure this week along with the broader market, which succumbed to the negative sentiment generated by U.S.-China trade tensions. However, they recouped some of these losses, ...


Chandler opioid manufacturer warns it may file for bankruptcy
Posted on Friday May 17, 2019

The pharmaceutical firm saw its stock plummet earlier this week after announcing it may have to seek Chapter 11 protection.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.